Skip to Content
Merck
All Photos(1)

Documents

SRP3160

Sigma-Aldrich

sRank Receptor human

recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture

Synonym(s):

ODAR (osteoclast differentiation and activation receptor), TNFRSF11A, TRANCE Receptor

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352200
NACRES:
NA.32

biological source

human

recombinant

expressed in E. coli

Assay

≥98% (HPLC)
≥98% (SDS-PAGE)

form

lyophilized

potency

30-50 ng/mL ED50

mol wt

19.3 kDa

packaging

pkg of 100 μg

technique(s)

cell culture | mammalian: suitable

impurities

<0.1 EU/μg endotoxin, tested

color

white

UniProt accession no.

shipped in

wet ice

storage temp.

−20°C

Gene Information

General description

Soluble receptor activator of nuclear factor-κB (sRANK) also known as TNF receptor superfamily member 11a (TNFRSF11A), is encoded by the gene mapped to human chromosome 18. The encoded protein belongs to the tumor necrosis factor (TNF) receptor superfamily. RANK is widely expressed in variety of tissues, including skeletal muscle, thymus, liver, colon, small intestine, adrenal gland, osteoclast, mammary gland epithelial cells, prostate and pancreas. Recombinant human sRANK receptor is a 19.3kDa polypeptide containing the TNFR homologous cysteine rich portion of the extracellular domain of RANK receptor (175 amino acid residues).

Biochem/physiol Actions

Soluble receptor activator of nuclear factor-κB (sRANK) plays a vital role in bone remodeling and fracture repair. Alterations in the RANK signaling increase the risk of susceptibility to expansile osteolysis and Paget disease of bone (PDB2). In addition, mutation of the gene coding for RANK/RANKL/OPG has also been observed in various skeletal disorders such as osteoporosis, glucocorticoid-induced bone loss, multiple myeloma, and rheumatoid arthritis. Binding of RANKL to its receptor RANK triggers the formation and differentiation of osteoclasts with the help of various transcription factors involved in modulation of osteoclastogenesis. RANK/RANKL/OPG might act as a potent therapeutic target for bone diseases.

Sequence

MQIAPPCTSE KHYEHLGRCC NKCEPGKYMS SKCTTTSDSV CLPCGPDEYL DSWNEEDKCL LHKVCDTGKA LVAVVAGNST TPRRCACTAG YHWSQDCECC RRNTECAPGL GAQHPLQLNK DTVCKPCLAG YFSDAFSSTD KCRPWTNCTF LGKRVEHHGT EKSDAVCSSS LPARK

Physical form

Lyophilized from 10 mM Sodium Phosphate, pH 7.2.

Reconstitution

Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

RANKL-RANK signaling in osteoclastogenesis and bone disease.
Wada T
Trends in Molecular Medicine, 12(1), 17-25 (2006)
CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications.
Vega D
The Journal of Clinical Endocrinology and Metabolism, 92(12), 4514-4521 (2007)
Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis.
Hughes AE
Nature Genetics, 24(1), 45-48 (2000)
Plasma and drainage fluid levels of soluble receptor activator of nuclear factor-kB (sRANK), soluble receptor activator of nuclear factor-kB ligand (sRANKL) and osteoprotegerin (OPG) during proximal humerus fracture healing.
Colombini A
International Orthopaedics, 35(5), 777-782 (2011)
H Hsu et al.
Proceedings of the National Academy of Sciences of the United States of America, 96(7), 3540-3545 (1999-03-31)
A receptor that mediates osteoprotegerin ligand (OPGL)-induced osteoclast differentiation and activation has been identified via genomic analysis of a primary osteoclast precursor cell cDNA library and is identical to the tumor necrosis factor receptor (TNFR) family member RANK. The RANK

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service